SCHEMBL6316770

SCHEMBL6316770

NC(=O)c1c(-c2ccsc2)noc1NC(=O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.53
PDGFRB P09619 1/20 0.52
KDR P35968 1/20 0.52
PTGS1 P23219 4/20 0.45
P2RX1 P51575 1/20 0.44
ADCY1 Q08828 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
KDM4E B2RXH2 3/20 0.43
MAPT P10636 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
ALDH1A1 P00352 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MCOLN3 Q8TDD5 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
KCNK3 O14649 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6316062 0.89 NPC1 (0.41) LMNAPDGFRBKDRPTGS1MEN1
SCHEMBL6321264 0.87 LMNA (0.55) LMNAPDGFRBKDRPTGS1P2RX1
SCHEMBL27610017 0.86 LMNA (0.46) LMNAPDGFRBKDRPTGS1P2RX1
SCHEMBL6322739 0.85 FLT3 (0.46) LMNAKDRKDM4EMEN1KMT2A
SCHEMBL6316187 0.84 KIT (0.46) KDRKDM4EMAPTMEN1KMT2A
SCHEMBL6316642 0.84 LMNA (0.58) LMNAPDGFRBKDRPTGS1P2RX1
SCHEMBL6315874 0.82 LMNA (0.53) LMNAPDGFRBKDRPTGS1MEN1
SCHEMBL6315689 0.82 FLT3 (0.48) LMNAKDM4EMAPTMEN1KMT2A
SCHEMBL6319814 0.82 LMNA (0.52) LMNAPDGFRBKDRPTGS1P2RX1
SCHEMBL6315543 0.81 TNIK (0.39) KDRKDM4EMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 LMNA 3334/4885PDGFRB 2474/4885KDR 3191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.